Bicara Therapeutics (NASDAQ:BCAX) is developing tumor-targeting bifunctional antibodies, with its lead candidate ficerasfusp alfa designed to address both EGFR and TGF-beta biology in cancer, company ...
Dental pulp regeneration remains a major clinical challenge. Researchers have discovered that SMAD7 directly forms a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results